Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 210 participants.
Also called NCT07613099
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose diagnostic
- Phase
- Phase 3
- Enrolled
- 210 participants
- Registry
-
NCT07613099
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07613099. Non-randomized; no masking; primary purpose diagnostic. Start 2026-09-18 (actual); primary completion 2031-05-26 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
- Condition
- Allogeneic Stem Cell Transplantation
- Condition
- Lung Allograft Transplantation
- Condition
- Interstitial Lung Disease
- Condition
- Acute Lung Injury
- Condition
- Pulmonary Arterial Hypertension
- Condition
- Cardiovascular Diseases
- Intervention (Drug)
- [18F]FAPI-74
- Intervention (Diagnostic test)
- 18F-FAPI-74 PET/CT Imaging
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Record details
- Record id
cardio:ct-nct07613099- Content hash
d08c2dced2e60a06396e38785415f8d6e01041056042d346e96026c91a7a8e1b